Células CAR-NK: una terapia emergente en inmuno-oncología

Jessica María Rodriguez Cortés

doi:10.22490/ECISA.9959

No. 7 (2025)

Published 2025-08-24

license

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Artículos

CAR-NK cells: an emerging therapy in immuno-oncology

DOI: https://doi.org/10.22490/ECISA.9959

Jessica María Rodriguez Cortés Universidad Nacional Abierta y a Distancia

PDF (Spanish)

Abstract
References

Cellular immunotherapy has revolutionized cancer treatment, especially through the use of chimeric antigen receptor T cells (CAR-T cells). However, CAR-modified natural killer (NK) cells are emerging as a promising alternative with significant advantages in safety, feasibility, and clinical applicability. This paper explores the current status of CAR-NK therapy development, their comparison with CAR-T, potential applications in hematological and solid tumors, and the main regulatory and manufacturing challenges facing this technology [1,2].

keywords: CAR-NK cells, cell therapies, cancer, inmuno-oncology., cell therapies, cancer, inmuno-oncology, CAR-NK cells

1. Klingemann H. Are natural killer cells superior CAR drivers? Oncoimmunology. 2014;3:e28147.

2. Daher M, Rezvani K. Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering. Curr Opin Immunol. 2018;51:146–153.

3. Liu E, Marin D, Banerjee P, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med. 2020;382:545–553.

4. Zhu H, Blum RH, Bernareggi D, et al. Metabolic reprogramming via deletion of CISH in human iPSC-derived NK cells promotes in vivo persistence and enhances antitumor activity. Cell Stem Cell. 2020;27(2):224–237.e6.

5. Rezvani K, et al. Clinical evaluation of CAR-NK cells: updates and perspectives. Front Immunol. 2021;12:673923.

6. Valeri A, Herberman RB. Challenges and strategies for enhancing CAR-NK cell therapy efficacy. J Hematol Oncol. 2022;15(1):22.

7. Vázquez Rodríguez A, Mendoza-Rincón JF. Células asesinas naturales con el receptor de antígeno quimérico (CAR-NK): terapia emergente contra el cáncer. NOVA. 2024;22(42):107–117.

8. Li Y, Hermanson DL, Moriarity BS, Kaufman DS. Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity. Cell Stem Cell. 2018;23(2):181–192.

9. Sarvaria A, Jawdat D, Madrigal JA, Saudemont A. Umbilical cord blood natural killer cells, their characteristics, and potential clinical applications. Front Immunol. 2017;8:329.

10. Gaudillière B, et al. Ethical and regulatory considerations for cell-based immunotherapy. Nat Med. 2020;26(1):18–23.

11. Salinas Pérez E, Martínez Quintero ÁM. Biomarcadores moleculares en inmunoterapia contra el cáncer: retos y oportunidades en Latinoamérica. NOVA. 2023;21(41):55–67.

12. Jiménez Ocampo HA, Rojas Gómez DM. Vigilancia inmunológica y evasión tumoral en carcinomas epiteliales: una revisión. NOVA. 2023;21(40):88–99.

license

How to Cite

Rodriguez Cortés, J. M. (2025). CAR-NK cells: an emerging therapy in immuno-oncology. Documentos De Trabajo ECISA, 7. https://doi.org/10.22490/ECISA.9959

Download Citation

Almétricas

Metrics

Metrics Loading ...